Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

LncRNA A1BGAS1 Serves as a Tumor Suppressor in Non-Small Cell Lung Cancer by Modulating the Expression of miR-3942-5P.

Created on 29 Oct 2026

Authors

Jiahui Du, Zhenhua Li, Chunqiang Wang, Xuexi Zhang

Published in

Journal of biochemical and molecular toxicology. Volume 40. Issue 11.

Abstract

Non-small cell lung cancer (NSCLC), the leading contributor to global cancer mortality, is associated with a notably unfavorable prognosis. This study aims to explore the regulatory interaction between A1BG-AS1 and miR-3942-5p and its molecular mechanisms. The level of A1BG-AS1 and miR-3942-5p in both tumor tissues and cell lines (BEAS-2B, A549, H226) were measured using qPCR. Functional effects of A1BG-AS1 overexpression in NSCLC cells were evaluated through CCK-8, flow cytometry, and Transwell assays. The interaction between A1BG-AS1 and miR-3942-5p was validated through dual-luciferase reporter assays and rescue studies. A1BG-AS1 expression was markedly reduced in both NSCLC tissues and cell lines. A1BG-AS1 expression was significantly associated with various clinical parameters. Overexpression of A1BG-AS1 suppressed NSCLC cell function. Mechanistically, A1BG-AS1 interacted with and negatively regulated miR-3942-5p, and the antitumor effects of A1BG-AS1 overexpression were reversed by miR-3942-5p mimics.A1BG-AS1 inhibits NSCLC tumor progression by targeting miR-3942-5p.

PMID:
42952240
Bibliographic data and abstract were imported from PubMed on 29 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 3
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement